Meropenem is a carbapenem antibiotic approved by the US Food and Drug Administration
for the treatment of complicated skin and skin-structure infections, complicated intra …

Objectives The pharmacodynamics of polymyxin/carbapenem combinations against
carbapenem-resistant Acinetobacter baumannii (CRAB) are largely unknown. Our objective …

BACKGROUND: β-Lactam antibiotics demonstrate time-dependent killing. Prolonged
infusion of these agents is commonly performed to optimize the time the unbound …

Background Beta-lactam anti-infective levels after standard dosing have been shown to be
subtherapeutic when renal clearance is augmented. Objective To determine if piperacillin …

Background Meropenem is a carbapenem antibiotic commonly used in critically ill patients
to treat severe infections. The available pharmacokinetic (PK) data has been mostly …

Extensively drug-resistant (XDR) Klebsiella pneumoniae is an emerging pathogen in
Singapore. With limited therapeutic options available, combination antibiotics may be the …

Objective We present our experience with five cases of pandrug-resistant Pseudomonas
aeruginosa ventilator-associated pneumonia (VAP) and analysis of risk factors. Design and …

Fosfomycin disodium is a potential therapeutic option to manage difficult-to-treat infections,
especially when combined with other antimicrobials. In this study, we evaluated the activity …

Over the last decade, there has been a growing appreciation for the use of in vitro and in
vivo infection models to generate robust and informative nonclinical PK/PD data to …

Nosocomial infections caused by strains Acinetobacter baumannii strands are a growing
clinical problem. The occurrence of multidrug-resistant strands is observed and that limits …